Stocks and Investing
Stocks and Investing
Wed, April 28, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, April 27, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Maintained (AXSM) at Strong Buy with Increased Target to $225 on, Apr 27th, 2021
Raghuram Selvaraju of HC Wainwright & Co., Maintained "Axsome Therapeutics, Inc." (AXSM) at Strong Buy with Increased Target from $210 to $225 on, Apr 27th, 2021.
Raghuram has made no other calls on AXSM in the last 4 months.
There are 2 other peers that have a rating on AXSM. Out of the 2 peers that are also analyzing AXSM, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Increased Target to $104 on, Tuesday, March 2nd, 2021
- Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $129 on, Friday, January 8th, 2021
Contributing Sources